Main navigation

Kathryn Winglee

Class 2009
Education BS, University of Washington

Dr. Bill Bishai

Current Position ORISE Bioinformatics Fellow

Centers for Disease Control and Prevention

Research Interests

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), infects one-third of the world’s population, and resistance to all known anti-mycobacterial agents is on the rise. I am interested in identifying the mechanism of action of novel compounds that have been shown to be effective against both drug susceptible and resistant M. tuberculosis.


Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis. Kubler A, Larsson C, Luna B, Andrade BB, Amaral EP, Urbanowski M, Orandle M, Bock K, Ammerman NC, Cheung LS, Winglee K, Halushka M, Park JK, Sher A, Friedland JS, Elkington PT, Bishai WR. J Infect Dis. 2015 Sep 27. pii: jiv45 PMID:26416658

Mutation of Rv2887, a marR-Like Gene, Confers Mycobacterium tuberculosis Resistance to an Imidazopyridine-Based Agent. Winglee K, Lun S, Pieroni M, Kozikowski A, Bishai W.Antimicrob Agents Chemother. 2015 Nov;59(11):6873-81. doi: 10.1128/AAC.01341-15. Epub 2015 Aug 24. PMID:26303802

Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactams. Lun S, Miranda D, Kubler A, Guo H, Maiga MC, Winglee K, Pelly S, Bishai WR. MBio. 2014 Sep 16;5(5):e01767-14. doi: 10.1128/mBio.01767-14.PMID:25227469

Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation. Kübler A, Luna B, Larsson C, Ammerman NC, Andrade BB, Orandle M, Bock KW, Xu Z, Bagci U, Molura DJ, Marshall J, Burns J, Winglee K, Ahidjo BA, Cheung LS, Klunk M, Jain SK, Kumar NP, Babu S, Sher A, Friedland JS, Elkington PT, Bishai WR. J Pathol. 2015 Feb;235(3):431-44. doi: 10.1002/path.4432. Epub 2014 Oct 6. PMID:25186281

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Antimicrob Agents Chemother. 2014;58(1):574-6. doi: 10.1128/AAC.01462-13. Epub 2013 Oct 14. PMID:24126586

Risk of tuberculosis reactivation with tofacitinib (CP-690550).Maiga M, Lun S, Guo H, Winglee K, Ammerman NC, Bishai WR. J Infect Dis. 2012 Jun;205(11):1705-8. doi: 10.1093/infdis/jis269. Epub 2012 Apr 3. PMID:22474037